Compare LOCL & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | PLUR |
|---|---|---|
| Founded | 2021 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8M | 18.5M |
| IPO Year | 2021 | 2001 |
| Metric | LOCL | PLUR |
|---|---|---|
| Price | $1.06 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 38.6K | 14.3K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.33 | 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,365,000.00 | $1,016,000.00 |
| Revenue This Year | $93.32 | $902.46 |
| Revenue Next Year | $25.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.82 | N/A |
| 52 Week Low | $0.95 | $0.90 |
| 52 Week High | $4.00 | $4.87 |
| Indicator | LOCL | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | N/A |
| Support Level | $0.98 | N/A |
| Resistance Level | $1.27 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 26.67 | 0.00 |
Local Bounti Corp is a controlled environment agriculture company. The business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides. The products of the company include living lettuce, leafy greens, herbs, and others.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.